Clinical trials studying the impact of ruxolitinib, a selective JAK1/2 inhibitor, on polycythemia vera and myelofibrosis demonstrated significant improvement in patient outcomes, leading to Food and Drug Administration (FDA) approval and widespread use of this agent for these diseases[16-22]. This evidence concerns the gene JAK1 and myelofibrosis.